Plasma cfDNA analysis of alectinib resistance-related gene alterations in the J-ALEX study.

ABSTRACT:

Background

Resistance to alectinib, the standard first-line therapy for anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancer (NSCLC), remains a major clinical challenge. This study aimed to investigate resistance mechanisms using next-generation sequencing (NGS) of plasma cell-free DNA (cfDNA).

Materials and methods

Plasma samples from 67 patients in the alectinib group of the J-ALEX study were collected at baseline, on day 57, and at treatment discontinuation. cfDNA was extracted and analyzed using NGS to detect ALK secondary mutations (SMs) and other resistance-related genetic alterations. Progression-free survival (PFS) was compared between patients with and without detectable SMs.

Results

Alectinib-resistant ALK SMs were detected in 9 of the 67 p

SUBMITTER: Sakaguchi H 

PROVIDER: S-EPMC12448013 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature